External-beam theranostic oncology company RefleXion Medical has officially announced the launch of the BIOGUIDE-X2 clinical study to expand indications for SCINTIX® biology-guided radiotherapy at Hackensack Meridian John Theurer Cancer Center.
Additionally, the company shared updates from the Centers for Medicare and Medicaid (CMS) Services and starting this year CMS will provide broader reimbursement for SCINTIX therapy, including new codes for freestanding cancer centers (FSC) and professional reimbursement for physicians in FSC and hospital outpatient departments.
“The achievement of these milestones sets the stage for substantial expansion in both the indications for and access to SCINTIX therapy,” Sean Shirvani, M.D., M.P.H., chief medical officer at RefleXion said via the press release. “Given that 40% of American cancer patients receive radiation therapy in freestanding centers1, securing reimbursement for these facilities was imperative, as it eliminates payment barriers for providers adopting new technologies and grants patients access to innovative treatment options.”
Per the statement, the Medicare updates simplify and expand reimbursement, allowing approximately 400,000 additional patients,2 including those suffering from metastatic disease, access to SCINTIX therapy and also provide support to physicians by introducing a professional payment coding mechanism as part of an effort to assist in the widespread adoption of the tech.
“We are also buoyed by the initiation of the BIOGUIDE-X2 clinical study, designed as a multi-cohort study for patients with cancers in the liver and abdomen as the first cohorts. We are grateful to our clinical champions at all our sites for their assistance in designing and implementing this study,” Shirvani added.
